Skip to main content Back to Top
Advertisement

12/2/2022

Sucralfate Tablets

Products Affected - Description

    • Carafate tablet, AbbVie, 1 gram, bottle, 100 count, NDC 58914-0171-10
    • Sucralfate tablet, Mylan (Viatris), 1 gram, unit-dose blister pack, 100 count, NDC 51079-0753-20
    • Sucralfate tablet, Teva, 1 gram, bottle, 90 count, NDC 00093-2210-98
    • Sucralfate tablet, Teva, 1 gram, bottle, 100 count, NDC 00093-2210-01
    • Sucralfate tablet, Teva, 1 gram, bottle, 500 count, NDC 00093-2210-05

Reason for the Shortage

    • AbbVie did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Viatris did not provide a reason for the shortage.

Available Products

    • Sucralfate tablet, Mylan (Viatris), 1 gram, bottle, 100 count, NDC 59762-0401-01
    • Sucralfate tablet, Mylan (Viatris), 1 gram, bottle, 500 count, NDC 59762-0401-05

Estimated Resupply Dates

    • Teva has sucralfate 1 gram tablets in 90 count, 100 count, and 500 count on back order and the company estimates a release date of early-December 2022.
    • Viatris has sucralfate 1 gram tablets in 100 count unit-dose packs on back order and the company estimates a release date of early-February 2023.
    • AbbVie has Carafate 1 gram tablets on back order and the company estimates a release date of late-January 2023.

Updated

Updated December 2, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 28, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.